TNF Pharmaceuticals (TNFA) announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha inhibitor drug isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded study is expected to evaluate TNF-a levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia. TNFA is currently conducting a Phase 2 clinical trial of isomyosamine as a treatment for aging-related sarcopenia. Based on statistically significant results from the smaller Phase 2a study, the company plans to launch a Phase 2b study early in the first quarter of 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA: